Amneal has set out the latest targets in its continuing push to unlock value from complex generics, unveiling a trio of US Food and Drug Administration filings for rivals to ProAir (albuterol) inhalation, Lumigan (bimatoprost) ophthalmic solution and Diprivan (propofol) emulsion.
Amneal Goes After ProAir, Lumigan And Diprivan With Latest Filings
Fresh ANDA Filings With FDA Reflect Firm’s Increasing Move Into Complex Generics
With a continuing focus on complex generics, Amneal has revealed a trio of US filings targeting ProAir, Lumigan and Diprivan.
